Suppr超能文献

Nek4 状态差异改变了对不同微管毒物的敏感性。

Nek4 status differentially alters sensitivity to distinct microtubule poisons.

机构信息

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.

出版信息

Cancer Res. 2010 Feb 1;70(3):1033-41. doi: 10.1158/0008-5472.CAN-09-2113. Epub 2010 Jan 26.

Abstract

Microtubule poisons are widely used in cancer treatment, but the factors determining the relative efficacy of different drugs in this class remain obscure. In this study, we identified the NIMA kinase Nek4 in a genetic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtubules. After Taxol treatment, Nek4 promoted microtubule outgrowth, whereas Nek4 deficiency impaired G(2)-M arrest and decreased formation of mitotic-like asters. In contrast, Nek4 deficiency sensitized cells to vincristine, which destabilizes microtubules. Therefore, Nek4 deficiency may either antagonize or agonize the effects of microtubule poisons, depending on how they affect microtubule polymerization. Of note, Nek4 gene maps to a commonly deleted locus in non-small cell lung cancer. Thus, Nek4 deletion in this disease may rationalize the use of particular types of microtubule poisons for lung cancer therapy.

摘要

微管毒物被广泛应用于癌症治疗,但在该类药物中,决定不同药物相对疗效的因素仍不清楚。在本研究中,我们通过遗传筛选鉴定了 NIMA 激酶 Nek4,该激酶是紫杉醇(一种稳定微管的化疗药物)反应的介质。紫杉醇处理后,Nek4 促进微管生长,而 Nek4 缺陷则损害 G2-M 阻滞并减少有丝分裂样星状体的形成。相反,Nek4 缺陷使细胞对长春新碱(一种破坏微管的药物)敏感。因此,Nek4 缺陷可能拮抗或激动微管毒物的作用,具体取决于它们如何影响微管聚合。值得注意的是,Nek4 基因位于非小细胞肺癌中常见的缺失位点。因此,在该疾病中 Nek4 的缺失可能合理化特定类型的微管毒物用于肺癌治疗。

相似文献

1
Nek4 status differentially alters sensitivity to distinct microtubule poisons.
Cancer Res. 2010 Feb 1;70(3):1033-41. doi: 10.1158/0008-5472.CAN-09-2113. Epub 2010 Jan 26.
5
Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Cell Physiol Biochem. 2020 Apr 8;54(2):303-320. doi: 10.33594/000000221.
6
Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Biochem Pharmacol. 2007 Jun 30;74(1):10-9. doi: 10.1016/j.bcp.2007.03.015. Epub 2007 Mar 24.
7
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Invest New Drugs. 2020 Jun;38(3):584-598. doi: 10.1007/s10637-019-00803-6. Epub 2019 Jun 8.
9
2-APCAs, the Novel Microtubule Targeting Agents Active Against Distinct Cancer Cell Lines.
Molecules. 2021 Jan 25;26(3):616. doi: 10.3390/molecules26030616.
10
Nek4 regulates entry into replicative senescence and the response to DNA damage in human fibroblasts.
Mol Cell Biol. 2012 Oct;32(19):3963-77. doi: 10.1128/MCB.00436-12. Epub 2012 Jul 30.

引用本文的文献

1
NEK kinases in cell cycle regulation, DNA damage response, and cancer progression.
Tissue Cell. 2025 Jun;94:102811. doi: 10.1016/j.tice.2025.102811. Epub 2025 Feb 28.
2
NEK4: prediction of available drug targets and common genetic linkages in bipolar disorder and major depressive disorder.
Front Psychiatry. 2025 Jan 30;16:1414015. doi: 10.3389/fpsyt.2025.1414015. eCollection 2025.
4
NEK Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types.
Cancers (Basel). 2023 Mar 30;15(7):2067. doi: 10.3390/cancers15072067.
5
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma.
Oncogene. 2022 Jun;41(24):3355-3369. doi: 10.1038/s41388-022-02330-w. Epub 2022 May 10.
7
In Mitosis You Are Not: The NIMA Family of Kinases in , Yeast, and Mammals.
Int J Mol Sci. 2022 Apr 6;23(7):4041. doi: 10.3390/ijms23074041.
8
On Broken Ne(c)ks and Broken DNA: The Role of Human NEKs in the DNA Damage Response.
Cells. 2021 Feb 27;10(3):507. doi: 10.3390/cells10030507.
9
Checking NEKs: Overcoming a Bottleneck in Human Diseases.
Molecules. 2020 Apr 13;25(8):1778. doi: 10.3390/molecules25081778.

本文引用的文献

1
Microtubule active agents: beyond the taxane frontier.
Clin Cancer Res. 2008 Nov 15;14(22):7167-72. doi: 10.1158/1078-0432.CCR-08-0169.
2
Current state of the art of new tubulin inhibitors in the clinic.
Curr Clin Pharmacol. 2006 Jan;1(1):57-70. doi: 10.2174/157488406775268200.
3
Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.
Cancer Cell. 2008 Aug 12;14(2):111-22. doi: 10.1016/j.ccr.2008.07.002. Epub 2008 Jul 24.
4
Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9053-8. doi: 10.1073/pnas.0803513105. Epub 2008 Jun 23.
5
A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
J Pharmacol Exp Ther. 2008 Feb;324(2):434-42. doi: 10.1124/jpet.107.128926. Epub 2007 Nov 6.
6
Phylogenetic analysis of the Neks reveals early diversification of ciliary-cell cycle kinases.
PLoS One. 2007 Oct 24;2(10):e1076. doi: 10.1371/journal.pone.0001076.
7
Mitotic regulation by NIMA-related kinases.
Cell Div. 2007 Aug 29;2:25. doi: 10.1186/1747-1028-2-25.
8
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Ann Oncol. 2007 Jul;18 Suppl 5:v3-8. doi: 10.1093/annonc/mdm172.
9
Mouse models of human non-small-cell lung cancer: raising the bar.
Cold Spring Harb Symp Quant Biol. 2005;70:241-50. doi: 10.1101/sqb.2005.70.037.
10
Caught Nek-ing: cilia and centrioles.
J Cell Sci. 2005 Nov 15;118(Pt 22):5161-9. doi: 10.1242/jcs.02681.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验